

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in this application.

Listing of Claims:

Claim 1 (withdrawn): Picornavirus, comprising in the non-coding region of its viral genome a nucleotide sequence corresponding to a cDNA sequence selected from the group consisting of SEQ ID NO: 1 (Ljungan 87-012)

```
AGTCTAGTCT TATCTTGTAT GTGTCCTGCA CTGAACTTGT TTCTGTCTCT 50
GGAGTGCTCT ACACTTCAGT AGGGGCTGTA CCCGGGCGGT CCCACTCTTC 100
ACAGGAATCT GCACAGGTGG CTTTCACCTC TGGACAGTGC ATTCCACACC 150
CGCTCCACGG TAGAAGATGA TGTGTGTCTT TGCTTGTGAA AAGCTTGTGA 200
AAATCGTGTG TAGGCGTAGC GGCTACTTGA GTGCCAGCGG ATTACCCCTA 250
GTGGTAACAC TAGC
```

and homologous sequences having at least 75% homology to the SEQ ID NO: 1, and further, causing mammalian disease.

Claim 2 (withdrawn): Picornavirus according to claim 1, wherein said homologous sequences have at least 80%, at least 85% or at least 90% homology to the SEQ ID NO: 1.

Claim 3 (withdrawn): Picornavirus according to claim 2, wherein said homologous sequence is one of SEQ ID NO: 2 (Ljungan 174F)

```

AGTCTAGTTT CATTCTGTGT GTGTTTGGCA CTGAAATTAT TTCTGTCTCT 50
GGGGTGCTTT ACACTTCAGT AGGGGCTGTA CCCGGGCGGT CCCACTCTTC 100
ACAGGAATNT GCACAGGTGG CTTTCACCTC TGGACAGTGC ATTCCACACC 150
CGCTCCACAG TAGAAGATGA TGTGTGTCTT TGCTTGTGAA AAGCTTGTGA 200
AAATCGTGTG TAGGCGTAGC GGNTACTTGA GTGCCAGCGG ACNACCCCTA 250
GTGGTAACAC TAGC

```

and

SEQ ID NO:3 (Ljungan 145SL)

```

AGTTTGGTTC TCTCTTGAGT GTGTTTTGTG TTAGCATAAT TTCTGTCTCT 50
AGAGTGCTTT ACACTCTAGT AGGGGCTGTA CCCGGGCGGT CCCACTCTTC 100
ACAGGAATCT GCACAGGTGG CTTTCACCTC TGGACAGTGC ATTCCATACC 150
CGCTCCACAA TAGAAGATGA TGTATATCTT TGTTTGTGAA ATGCTCATGA 200
AACGTGTGTG TAGGCGTAGC GGCTACTTGA ATGCCAGCGG AACCCCCCTA 250
GTGGTAACAC TAGC.

```

Claim 4 (currently amended): A protein comprising
an amino acid sequence selected from the group consisting
of SEQ ID NO: 4 (partial structural protein of Ljungan
145SL)

```

Lys Asp Leu Met Glu Ile Ala Arg Met Pro Ser Val Tyr Lys Gly Glu
      5                      10                      15
Arg Thr Glu Pro Gly Gly Thr Asn Gly Tyr Phe Gln Trp Ser His Thr
      20                      25                      30
His Ser Pro Ile Asn Trp Val Phe Asp Gly Gly Ile His Leu Glu Asp
      35                      40                      45
Met Pro Asn Leu Asn Leu Phe Ser Ser Cys Tyr Asn Tyr Trp Arg Gly
      50                      55                      60
Ser Thr Val Leu Lys Leu Thr Val Tyr Ala Ser Thr Phe Asn Lys Gly
      65                      70                      75                      80
Arg Leu Arg Met Ala Phe Phe Pro Ile Met Met Gln Gly Thr Gln Arg
      85                      90                      95
Lys Lys His Lys Cys Leu Phe Met Val Cys Asp Ile Gly Leu Asn Asn
      100                     105                     110
Thr Phe Glu Met Thr Ile Pro Tyr Thr Trp Gly Asn Trp Met Arg Pro
      115                     120                     125
Thr Arg Gly Ser Val Ile Gly Trp Leu Arg Ile Asp Val Leu Asn Arg
      130                     135                     140
Leu Thr Tyr Asn Ser Ser Pro Asn Ala Val Asn Cys Ile Leu Gln
      145                     150                     155                     160
Val Lys Met Gly Asn Asp Ala Lys Phe Met Val Pro Thr Thr Ser Asn
      165                     170                     175
Ile Val Trp,

```

~~and homologous sequences~~ or an amino acid sequence having at least 75% identical homology to the amino acid sequence of SEQ ID NO: 4, and antigenic fragments of the sequences.

Claim 5 (withdrawn): Antiserum or antibody directed against a structural protein of the virus according to claim 1.

Claim 6 (canceled).

Claim 7 (currently amended): A diagnostic kit comprising a protein according to claim 4 ~~or claim 17 or an antibody binding part thereof~~.

Claim 8 (canceled).

Claim 9 (currently amended): The vaccine according to claim 15 or 18 ~~which additionally comprises~~ further comprising an adjuvant.

Claim 10 (canceled).

Claim 11 (currently amended): A pharmaceutical composition ~~for treating or preventing infection by a virus in a mammal, said virus comprising in the non coding region of its viral genome a nucleotide sequence corresponding to a cDNA sequence selected from the group consisting of SEQ~~

~~ID NO: 1 and sequences at least 75% homologous to SEQ ID NO: 1, said pharmaceutical composition comprising a protein according to claim 4 or claim 17 or an antibody binding part thereof.~~

Claims 12-14 (canceled).

Claim 15 (currently amended): A vaccine ~~having as an immunizing or neutralizing component~~ comprising a protein according to claim 4 ~~or claim 17 or an antibody binding part thereof.~~

Claim 16 (currently amended): A method for preventing or treating infection in a mammal, including a human, by a virus comprising in the non-coding region of its viral genome a nucleotide sequence ~~corresponding to a cDNA sequence~~ selected from the group consisting of SEQ ID NO: 1 and sequences at least 75% identical ~~homologous~~ to SEQ ID NO: 1, said method comprising administering to said mammal a prophylactically or therapeutically effective amount of a composition selected from the group consisting of:

(a) a protein according to claim 4 ~~or claim 17 or an antibody binding part thereof;~~

(b) a pharmaceutical composition according to claim 11; and

(c) a vaccine according to any one of claims 9, 15 or 18.

Claim 17 (canceled).

Claim 18 (currently amended): The vaccine according to claim 15, said vaccine ~~additionally~~ further comprising a subunit of a virus, said virus comprising in the non-coding region of its viral genome a nucleotide sequence ~~corresponding to a cDNA sequence~~ selected from the group consisting of SEQ ID NO: 1 and sequences at least 75% identical ~~homologous~~ to SEQ ID NO: 1.

Claim 19 (canceled).